Dew--I'm not sure, but my understanding is that companies like IMCL licence phage display technology from DYAX and use the technology themselves to isolate antibodies directed toward specific targets.
Here is a patent for anti-FGFR antibodies generated by IMCL using DYAX phage technology. Note that IMCL is the only assignee listed on the the patent.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.